echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sun piaoyang, Hengrui pharmaceutical: China's pharmaceutical innovation has high investment, high risk, but not necessarily high return

    Sun piaoyang, Hengrui pharmaceutical: China's pharmaceutical innovation has high investment, high risk, but not necessarily high return

    • Last Update: 2019-03-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    This year marks the 70th anniversary of the founding of the people's Republic of China and 40 years of reform and opening up Looking back on the achievements of these years, sun piaoyang, chairman of Hengrui pharmaceutical, believes that China's pharmaceutical industry has made remarkable achievements In China, the total sales value of China's pharmaceutical industry in 1978 was 7.28 billion yuan, reaching 2.9 trillion yuan by the end of 2017 In the past 40 years, there has been a 400 fold increase In the world, the scale of China's pharmaceutical market is second only to that of the United States, which has opened a gap with European countries and Japan The development of pharmaceutical industry also brings social effects The main health indicators of Chinese residents have been significantly improved, the life expectancy of the population has increased from 67.9 in 1981 to 76.7 in 2017, and the maternal and infant mortality rates have declined In terms of R & D, as of January 2018, there are more than 4100 new drug R & D enterprises in the world, and the number of new drug R & D enterprises in China ranks third with that in Canada, accounting for 5% of the world's total; the number of clinical R & D initiated in China ranks fourth in the world; and the number of biological similar drug R & D in China ranks first in the world Especially after 2010, China's R & D capacity has been greatly improved, and the country has promoted the implementation of several major projects Sun piaoyang, chairman of Hengrui pharmaceutical, said at the Symposium of CPPCC members of the people's Congress of the people's Republic of China on "voice and responsibility" in 2019 that in the 70th anniversary of the founding of the people's Republic of China and the 40th anniversary of reform and opening up, China's pharmaceutical industry has narrowed the gap with developed countries and improved the country's innovation and competitiveness But it also shows that the health of Chinese people still needs the development of Chinese enterprises In the past 70 years, a large number of medical products and technologies have been guaranteed by Chinese pharmaceutical enterprises Looking forward to the 2030 health plan, the health of Chinese people will shift from the back-end to the front-end, from treatment to prevention, and the guiding ideology will change In terms of the scale of medicine, China's health industry currently accounts for only 5% of GDP, while the United States accounts for 15%, Japan and Europe account for 10%, and China still lags far behind the world Therefore, in the future, the potential of the pharmaceutical market is huge Many clinical diseases need effective drugs To achieve the 2030 plan, innovation and R & D of Chinese pharmaceutical and medical equipment enterprises are also needed For the pharmaceutical industry, the two focuses of sun piaoyang's representative are respectively generic drugs and innovative R & D he believes that: first, generic drugs: generic drugs are still the cornerstone of health protection for China's 1.4 billion population, and both developed and developing countries have the largest proportion of generic prescriptions Generic drugs account for 90% of prescriptions in the United States and Europe, while new drugs only account for 10% Although the sales amount of patent drugs is large, generic drugs are still the cornerstone of disease treatment Therefore, the implementation effect of China's generic drug policy is of great significance to the protection of national health China's generic drug policy should continue to advance steadily to ensure that the quality of generic drugs is reliable, the price is reasonable and the supply is sufficient Specifically, the state should set the payment price of medical insurance, and the market needs free competition Support private enterprises and brand imitation, and encourage generic drugs to go out and participate in international market competition 2、 Innovative R & D: at present, China's pharmaceutical innovation has the characteristics of high investment, high risk and long cycle, but whether it can achieve high return is still worth observing First, in terms of policy, the state should continue to support innovation In recent years, China's policy environment for innovation has continued to improve, with the acceleration of medical insurance and the improvement of intellectual property protection With the continuous development of innovation in China, policies need to be updated to adapt to the changes of innovation environment Taking the basic innovation of our country as an example, the policy of production, teaching and research ensures the cooperation between universities and enterprises, and promotes universities to carry out basic research and development, and shortens the industrial chain cycle Secondly, in terms of review and approval, innovative drugs in the United States can enter clinical research within 30 days, and China needs to further shorten the gap with foreign countries For drug evaluation rules, they should be more in line with the development law of innovative drugs Therefore, this year's amendment of China's drug administration law requires more pharmaceutical enterprises to participate in the proposal Thirdly, in terms of medical insurance, the state has adopted a series of medical insurance policies to introduce imported innovative drugs to solve the urgent medical problems of patients, but all of them depend on the state to cover the bottom, so the development of commercial insurance is also an urgent problem And it is also a key for pharmaceutical companies to put innovation into the market quickly In addition, the protection of intellectual property rights, the extension of patent period and the protection of new drug data are also an important part of encouraging the innovation of Chinese enterprises If intellectual property rights cannot be effectively protected and encouraged, and innovation has no return, a virtuous circle of industry cannot be formed Finally, the policy stability is not strong, the enthusiasm of enterprise innovation will also be frustrated In the past two days, the leaders of China's Medical Insurance Bureau said that the policy will be adjusted again immediately, and the guarantee will be more standardized and clear Sun piaoyang believes that "with the increasingly clear guidance of China's policies and the unremitting efforts of China's private entrepreneurs, we believe that China's future innovation will continue to increase, narrow the gap with foreign countries, and promote the healthy development of Chinese people."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.